



सत्यमेव जयते



IN-UK47299070679284W


INDIA NON JUDICIAL

Government of Uttarakhand

e-Stamp



Certificate No. : IN-UK47299070679284W
Certificate Issued Date : 26-Sep-2024 11:38 AM
Account Reference : NONACC (SV)/ uk1264704/ DOIWALA/ UK-DH
Unique Doc. Reference : SUBIN-UKUK126470401588215403467W
Purchased by : SRHU JOLLYGRANT
Description of Document : Article 5 Agreement or Memorandum of an agreement
Property Description : NA
Consideration Price (Rs.) : 0
 (Zero)
First Party : SRHU JOLLYGRANT
Second Party : KV CLINICAL RESEARCH PVT LTD
Stamp Duty Paid By : SRHU JOLLYGRANT
Stamp Duty Amount(Rs.) : 100
 (One Hundred only)



Please write or type below this line

AGREEMENT FOR CLINICAL TRIAL

This Contract for Provision of Site Management Solutions & Services (“Contract”) is made on this **26th Day of September 2024** (“Effective Date”)

By and Between



Page 1 of 14

Statutory Alert:

1. The authenticity of this Stamp certificate should be verified at 'www.shcilestamp.com' or using e-Stamp Mobile App of Stock Holding. Any discrepancy in the details on this Certificate and as available on the website / Mobile App renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority.

Swami Rama Himalayan University (SRHU), a University established under section 2(f) of the UGC Act and enacted vide Uttarakhand State Act having its registered office at Swami Ram Nagar, Jolly Grant, Doiwala, Dehradun, Uttarakhand 248016, (here-in-after referred to as the "Study site") of one part

And

KV Clinical Research Pvt Ltd (A site Management Organization-SMO) a company under the company Act 2013 (18 of 2013) and Corporate Identity Number of the company is U73200CT2020PTC010704 having its office at Office No. 616, Sixth Floor Golden Trade Center, New Rajendra Nagar Raipur-492001, Chhattisgarh (here-in after referred to as the "KVCR") of the second part.

KVCR and Study site (SRHU) are hereinafter collectively referred to as the "Parties" or singularly as the "Party" as the context requires

KVCR is a India based SMO company that specializes in partnering with Pharmaceutical, Biotechnology and Medical Device firms to assist with Clinical Research and Site Management activities, with particular expertise in Site Management, Project Management and Clinical Research Expertise in India.

KVCR is desirous of working with Investigator & Study site for the purpose of conducting ICH-GCP compliant Phase I-II (Wherever Possible), Phase III-IV Clinical Trials for new drugs, Bio-similar, medical devices and generic drugs.

Swami Rama Himalayan University (SRHU), a top private university in Dehradun endeavours to transform lives through holistic approach to education, providing integrated health care services and effective rural development and social outreach programs. With a rich legacy of Himalayan Hospital & Himalayan Institute of Medical Sciences, the first and the largest NABH accredited private teaching hospital and medical college of Uttarakhand, SRHU has been providing a platform to the youth, for a decade, to learn and transform into efficient, effective, ethical and committed professionals. SRHU is the only university in Dehradun, Uttarakhand that has a dedicated multispecialty Himalayan Hospital, Cancer Research Institute, Ayurveda Center and Rural Development Institute, all under one roof, besides eight schools and colleges namely: Himalayan Institute of Medical Sciences, Himalayan College of Nursing, Himalayan School of Management Studies, Himalayan School of Science & Technology, Himalayan School of Bio Sciences, Himalayan School of Yoga Science. Students have a range of options to pursue their academic aspirations and further advance their learnings through interdisciplinary and multidisciplinary programs and research. In addition, there are ample opportunities for extra-curricular & co-curricular activities necessary to become an all-rounder. Furthermore, mentoring, meditation & Science of Joyful Living (SoJL) workshops help students grow as complete individuals.



KV Clinical Research Pvt Ltd and Swami Rama Himalayan University intend to conclude a contract for Site Management solutions & services to facilitate the clinical trial study at teaching Hospital of Swami Rama Himalayan University, India.

A. Definition:

1. **“Sponsor”** shall mean an individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical study or trial at study site. Sponsor shall be the owner of the Clinical Trial Protocol and is interested in carrying out the said Clinical Trial, through the KVCR & PRINCIPAL INVESTIGATOR at study site.
2. **“Site Management Organization (SMO)”** is a company that provides clinical trial management services to pharmaceutical, biotech, medical companies or Medical Institutions. SMOs help sponsors streamline their administrative processes while ensuring that all regulatory requirements are met. They also support Clinical Research Organisation (CRO) and clinical investigators at the site with startup, monitoring, and closeout responsibilities
3. **“Principal investigator (PI)”** is a qualified and experienced professional in conducting the Study.
4. **“Intellectual Property”** mean patents, trademarks, rights in domain names, designs, copyrights, database rights (whether or not any of these is registered and including applications for registration of any such thing) and all rights or forms of protection of a similar nature of having equivalent or similar effect to any of these which may subsist anywhere in the world;
5. **“Institution”** means Swami Rama Himalayan University (SRHU), Jolly Grant, Dehradun
6. **“Study Sites”** means and include Swami Rama Himalayan University (SRHU), Jolly Grant, Dehradun
7. **“Clinical Trials”** means an investigation to be conducted at a Trial site in accordance to an approved Protocol,
8. **“Contract Research Organization or Clinical Research Organization (CRO)”** is a service organization that provides support to the pharmaceutical and biotechnology industries in the form of outsourced pharmaceutical research services (for both drugs and medical devices).
9. **“Serious Adverse Event (SAE)”** shall mean only any untoward medical condition that occurs at any dose:
 - a. Results in death,
 - b. Is Life-threatening,
 - c. Requires inpatient hospitalization or prolongation of existing hospitalization,
 - d. Results in persistent or significant disability/incapacity, or
 - e. Is a congenital anomaly/birth defect



B. Roles and Responsibilities of SRHU


1. Study site (SRHU) agrees to enter into a confidentiality agreement with Sponsor and KVCR.
2. The basic requirement/infrastructure for conducting clinical trials will be provided by the Study site i.e. room, Deep freezer and other requirements which will mention in protocols.

C. Roles and Responsibilities of KVCR

1. Clinical Trials which come to Study site through KVCR shall be handled by KVCR.
2. The site provide only space and logistics shall be provided by KVCR for the staff.
3. KVCR will appoint a trained Clinical Research coordinator (herein after referred as CRC) at the start of the trial at study site & would be responsible for all trial related statutory documentation and permissions.
4. KVCR will appoint a Project Manager (here in after referred as PM) who will be responsible to coordinate and over-see the progress and management of CRC activities and trial, regular visit to study site to ensure data- quality and resolve screening/recruitment/ general issues, if any, follow-up on post- monitoring action elements and study specific training needs and provide regular back-up to study site and Sponsor on trial progress.
5. KVCR will appoint a Quality Manager (herein after referred as QM) who will be responsible to check and ensure adherence to the protocol, record keeping and record retention as per the Protocol and applicable regulatory requirements.
6. Project Management, Quality Management and Study Co-ordination will be appointed by KVCR. KVCR personnel, PM and CRC will assist study site and sponsor in all trial related activities. The salaries of the Project Manager, Quality Manager & Clinical Research Coordinator will be paid by KVCR. All statutory requirement related to the employment of the staff appointed by the KVCR shall be fulfilled by the KVCR.
7. KVCR will bear all the administrative cost related to the various activities undertaken by PM, CRC or any other staff placed by KVCR, which includes telecommunication, travel cost to meet various clients across India and abroad, training cost at various centres across India and abroad.

D. KVCR & Study site have considered & reached an understanding on the following:

1. All agreement for the studies (Clinical Trials) will be quadripartite agreement i.e Sponsor/ CRO, Institute, PI & KVCR.
2. The variable details of study budget in INR is as follows:



S. No	Particulars	Payment to	Amount
a.	IEC Review Fees	Institutional Ethics Committee	As per Ethics Committee SOP
b.	Institutional Overhead (20% of PI and Co-I) Note: If total amount of PI and Co-I is 100 rupees, then IOH will be 20 rupees, apart from 100 rupees.	SRHU	20% (Amount mentioned in Clinical Trial Agreement of individual study)
c.	Nursing/Phlebotomist Charges	SRHU	Amount mentioned in Clinical Trial Agreement of individual study
d.	CRC, Data Entry Operator, Back-up CRC, QA CRC	KV Clinical Research	Amount mentioned in Clinical Trial Agreement of individual study
e.	Laboratory Charges (If doing at hospital)	SRHU	Amount mentioned in Clinical Trial Agreement of individual study
f.	Bed Charges	SRHU	Amount mentioned in Clinical Trial Agreement of individual study
g.	Administration Charges (Courier, Stationary etc.)	KV Clinical Research	Amount mentioned in Clinical Trial Agreement of individual study
h.	Laboratory Charges (If doing from outside)	KV Clinical Research	Amount mentioned in Clinical Trial Agreement of individual study



			individual study
i.	Principal Investigator & Co-Investigator Charges	KV Clinical Research routed through hospital (SRHU)	35% (Amount mentioned in Clinical Trial Agreement of individual study for Principal Investigator including GST). If SRHU getting 100 INR+GST. The 35 INR only will be paid to KVCR including GST.
j.	Principal Investigator & Co-Investigator	SRHU	65% (Amount mentioned in Clinical Trial Agreement of individual study for Principal Investigator)

3. In quadripartite agreement i.e Sponsor/ CRO, Study site, PI & KVCR for different studies at the time of initiate of study, the total fee will be shared between the study site & KVCR . The budget will be received from the CRO/Sponsor on basis of actual work done i.e. number of patients randomized or visits completed.

- a) The payment for PI, Co-I, IOH and Lab investigations will be paid to Institute and KVCR (SMO) related payments (CRC, Data Entry Operator, Back-up CRC, QA CRC, Lab payment if done outside) will be directly paid to KV Clinical Research accounts.
- b) Getting payment from sponsor and giving to KVCR (SMO) (35% of PI & Co-I Charges), PI and Co-I shall be the responsibility of SRHU.

Note: The invoice from KVCR will be generated and submitted to SRHU within 15 days of receiving payment from the sponsor. The payment will be disbursed within 30 days after the invoice is received.

- c) The payment distribution should be clearly mentioned in each trial agreements.



- d) Payment distribution must be done on quarterly basis or once received from sponsor or at the time of completion of study, whichever will be earlier.
- e) Clinical Trial Agreement of individual study will contain two accounts details wherever possible. One account details of SRHU and Another of KVCR. Account Details are:

Financial terms & condition for the quadripartite agreement (PI, Institute, Sponsor or CRO & SMO):

Approval of Service/Supply Rates

All service and supply rates to be included in the agreement must be reviewed and approved by the competent authority before being finalized.

Exclusion of GST in MoU

The rates mentioned in the Memorandum of Understanding (MoU) should be exclusive of GST (Goods and Services Tax). Any applicable GST will be added separately to the total.

GST Charged Extra

GST shall be charged additionally as per the applicable rates and rules at the time of invoicing.

Billing Time and Frequency

The time frame and frequency of billing (e.g., monthly, quarterly, or per milestone) must be clearly stated in the agreement to avoid any confusion on payment schedules.

Service Description & HSN/SAC Code

The specific service name and relevant HSN (Harmonized System of Nomenclature) or SAC (Services Accounting Code) must be included in the agreement to comply with legal and tax requirements.

Payment Terms and Credit Period

The credit period or time allowed for payment after invoicing or the occurrence of key events should be clearly defined. This includes when payments are due after specific deliverables or milestones are met, ensuring clarity on the payment terms.



4. Payment for Institution related payments:

Payee Name (or Institution)	Swami Rama Himalayan University
Payee Address	Swami Rama Himalayan University, Swami Ram Nagar, Jolly Grant Dehradun 248016
Bank Name and Address	State Bank of India, HIHT, Jolly Grant
Cheque /Draft (in favor of)	Swami Rama Himalayan University
Account Number	33082676422
PAN Card Number	AAAJH0463L
GST Number	05AAAJH0463LIZC
IFSC Code	SBIN0010580

For SMO Related Payments:

Payee Name (or Institution)	KV Clinical Research Private Limited
Payee Address	Office No. 616, Golden Trade Center, New Rajendra Nagar, Raipur-492001, Chhattisgarh, India
Bank Name and Address	HDFC Bank, Devendra Nagar, Raipur
Cheque/Draft (in favor of)	KV Clinical Research Private Limited
Account Number	5020005851767



PAN Card Number	AAICK3564G
GST Number	22AAICK3564G1ZN
IFSC Code	HDFC0000152
Contact person for payments	Dr. Kirti Kumar Patel

5. SAE (Serious Adverse Event) shall be paid by sponsor direct to study site, which will depend upon the individual study agreement.
6. KVCR shall be exclusively conducting/ managing Clinical Research activities for Clinical trial protocols at the study site during the tenure of the studies. Study site under any circumstances shall not terminate this agreement during an ongoing study.

E. STUDY SPECIFIC MATERIAL & RIGHT TO USE:

- a) The KVCR or the sponsor shall provide the institution with the data and documents needed for conducting the clinical research activities and guaranteeing the safety of the subjects.
- b) The data and documents provided by the sponsor may be used solely for the conduct of clinical trials in accordance with this agreement.

F. DISCLOSURE OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION:

- a) KVCR & sponsor shall comply with all applicable laws and regulations regarding subject data privacy. In addition, sponsor will review and approve the informed consent and Authorization documents (collectively, the "Authorization Documents") relating to the use and disclosure of individually identifiable health information of subjects enrolled in the Study ("Health Information"), including receipt and use of Health Information by SPONSOR.
- b) SPONSOR will require that any party to whom SPONSOR discloses Health Information ("Recipient") agrees, to use and disclose the Health Information only as permitted in the Authorization Documents and in accordance with all applicable laws and regulations. The Authorization Documents will not authorize the SPONSOR or any Recipient to use Health Information to recruit research subjects to additional studies, to advertise additional studies or products or to perform marketing or marketing research.



G. CONFIDENTIAL INFORMATION:

a) During the term of this study agreement, for a period of five (03) years & after termination of this study, neither party shall disclose or use for any purpose other than performance of the study, any information including, but not limited to, any and all trade secrets, know-how, privileged records or other confidential or proprietary information and data both technical and non-technical (except as required under law disclosure to any governmental authority or any other person under the provisions of any applicable law, and also disclosure to their professional advisors/auditors and the like), disclosed by either party to the other ("confidential information"). Confidential information shall be in writing, clearly marked "confidential information" and sent by the either party directly to the principal investigator for this study.

b) Both parties shall hold in confidence the identity of any subject and shall comply with all applicable law(s) regarding the confidentiality of such subject's records.

c) Each party shall promptly return to the other party any confidential information no longer needed for the purposes of this agreement or if so requested by the other party.

H. INTELLECTUAL PROPERTY:


It is expressly agreed that the Study Site retains all rights, title, and interest in and to its pre-existing intellectual property, including any patents, copyrights, trademarks, trade secrets, methodologies, and proprietary technologies that are owned or controlled by the Study Site prior to the commencement of the clinical trial. All other inventions develop under this agreement (other inventions) that are developed solely by Institution shall be owned by Institution.

I. SEVERABILITY:

The invalidity or unenforceability of any term or provision of this agreement shall not affect the validity or enforceability of any other term or provision of this agreement.

J. FORCE MAJEURE:

Any delay or failure of a party hereto to perform its obligations hereunder will be excused if and to the extent that it was caused by an event or occurrence beyond such party's reasonable control and without its fault or negligence ("force majeure"). Force majeure includes, but is not limited to, acts of god, actions by any government authority, fires, floods, windstorms, explosions, riots natural disasters, wars, sabotage or acts of terrorism, pandemic. A party claiming Force Majeure must provide the other party with written notice of such delay (including the anticipated duration of the delay) within ten (10) days of the occurrence of Force Majeure. If the delay lasts more than ninety (90) days, either Party may terminate this Agreement upon written notice. Regardless of whether this Agreement



is terminated or naturally expires, SPONSOR shall be responsible for payment for all services or procedures actually performed in compliance with the study protocol and all non-cancellable Institution expenses incurred or obligated prior to termination or expiration and shall remit such total within thirty (30) days of Institution's written request for final payment. In the event of any overpayment by SPONSOR/CRO, Institution shall refund such overpayment to SPONSOR/CRO

K. WAIVER:

No waiver of any term, provision or condition of this agreement, whether by conduct or otherwise in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of the same term, provision or condition, or of any other term, provision or condition of this agreement.

L. RELATIONSHIP OF THE PARTIES:

The relationship of sponsor/CRO to institution and investigator shall be that of an independent entity and none of the parties shall hold itself out to third parties as purporting to act as, or on behalf of, the other party hereto.

M. USE OF OTHER PARTIES NAME:

Neither the sponsor nor the institution shall use directly or by implication the names of the other party, nor any of the other party's affiliates or contractors, nor any abbreviations thereof, or of any staff member, faculty member, student, or employee of the other party in connection with any products, publicity, promotion, financing, advertising, or other public disclosure without the prior written permission of the other party.

N. NOTICES:

That any notice, consent, waiver and/or other communication pursuant to this agreement must be in writing signed by the person serving it, or by a person duly authorized by the person serving it, and will be deemed to have been duly given when (a) delivered by hand (with written confirmation of receipt); or (b) when received by the addressee, if sent by a recognized overnight delivery service (receipt requested), in each case to the designated persons and the appropriate addresses mentioned at the end of this agreement.

O. REPRESENTATION AND WARRANTIES:

- a. Each Party represents to the other that it has the necessary right and authority to enter into this Agreement and to the best of its knowledge, it is not party to any agreement which would prevent it from fulfilling its obligations under this Agreement.
- b. KVCR warrants to SRHU that it shall have and maintain appropriate/applicable licenses, approvals, permits, certifications and the like necessary to lawfully perform its obligations under this Agreement.



P. INDEMNITY

- a. KVCR/SPONSOR shall jointly and/or individually indemnify, defend and hold harmless the Institution, Investigator, and/or other affiliated and cooperating hospitals and institutions, as well as the directors, officers, agents, employees, students, the members of their Institutional Review Boards, and others holding appointments within those institutions and their respective heirs, successors, and assigns (collectively "Institution Indemnities"), from any liability, loss, or damage they may suffer as a result of claims or judgments that arise from the Institution Indemnities' participation in and/or performance of the subject Study. KVCR/SPONSOR shall employ attorneys of its own selection and will be responsible for all expenses that result from employing a vigorous, diligent defense of Institution Indemnities, regardless of whether any claims are rightfully or wrongfully brought or filed.
- b. Sponsor/CRO shall indemnify all Subjects for any damage or loss, including all medical expenses incurred for the emergency and/or long-term treatment of any injury that is directly a result of Subjects' participation in the Study and/or the use of the Study Drug/Device or the performance of any other intervention required by the Protocol or any SAE (Serious Adverse Event) routed through study site.
- c. SRHU/Hospitals functioning under Institutions will not be responsible for any emergency/casualty/Serious Adverse Event happened during the ongoing trail. Notwithstanding any other terms contained in this Agreement, the Sponsor/CRO will reimburse the Institution for any reasonable, necessary and properly documented medical expenses directly as well indirectly related to a Study Subject's SAE in accordance with the provisions of the agreement
- d. The Site Management Organization (SMO) agrees to indemnify, defend, and hold harmless the Study Site, its affiliates, officers, directors, employees, agents, and investigators (collectively, the "Indemnified Parties") from and against any and all claims, liabilities, damages, losses, costs, and expenses (including reasonable attorney's fees) arising out of or relating to:
 - i. Any injury or harm to participants in the clinical trial that is directly caused by the SMO's negligence, willful misconduct, or failure to comply with applicable laws, regulations, or the terms of this Agreement;
 - ii. Any breach of the SMO's representations, warranties, or obligations under this Agreement;
 - iii. Any third-party claims arising out of or related to the SMO's activities in conducting the clinical trial at the Study Site.

Q. AMENDMENTS:

This Agreement may only be amended by the mutual written consent of both the parties.



R. TERM & TERMINATION:


- i. This agreement will be effective for minimum of 3 years from the date of agreement and after 3 years and can further be extended as mutually agreed between both the parties.
- ii. Either party may terminate this Agreement for any reason by providing the other party written notice of termination at least 9 months in advance. The notice shall specify the effective date of termination.
- iii. Notwithstanding the termination of this Agreement, any ongoing studies, projects, or obligations that were commenced prior to the issuance of the termination notice shall continue without interruption until their completion, unless otherwise agreed upon by both parties in writing.
- iv. Upon the completion of any ongoing study, each party shall fulfill any remaining obligations under this Agreement, including but not limited to the submission of reports, data, or other deliverables related to the study.
- v. Either party may forthwith terminate this Agreement by written intimation to the other Party if the other Party goes into liquidation or is wound up or dissolution proceedings are initiated or if a provisional liquidator or receiver is appointed to take possession of its undertakings, business or assets

S. DUTY TO UPDATE REGARDING SAFETY INFORMATION:

KVCR/SPONSOR shall notify Investigator in writing of any subject safety issues that may arise during the course of the Study and, thereafter, in accordance with concerned authorities' requirements. In addition, if KVCR/SPONSOR becomes aware of any findings through its site monitoring process that may possibly affect the safety or welfare of subjects enrolled in the Study, KVCR/SPONSOR will notify the Institution/investigator through the Institution's authorized representative.

T. GOVERNING LAWS AND DISPUTES RESOLUTION

- i. This Agreement shall be governed by and construed in accordance with the laws of India.
- ii. That any dispute and/or difference arising out of or relating to this Agreement, including interpretation of its terms shall be resolved amicably through joint discussion by the authorized representatives of both the parties.
- iii. That in case dispute is not resolved through joint discussion, same shall be finally settled through arbitration by a sole arbitrator mutually appointed by the Parties, as per the provisions of the Arbitration and Conciliation Act, 1996, as amended from time to time. In the circumstance that parties fail to appoint a sole arbitrator then the Parties shall appoint one arbitrator each who shall in turn jointly appoint the third arbitrator. The arbitration proceedings shall be conducted in English language and held at Dehradun, Uttarakhand, India.



[Handwritten signature]



- iv. The award of the arbitrator shall be final and binding on the Parties. However, the final jurisdiction shall lie with the courts of Dehradun, Uttarakhand, India.
- v. Each of the Parties hereby expressly submits to the jurisdiction of the courts of Dehradun, Uttarakhand, India.

We hereby agree to the conditions in this agreement:


Signature of the Swami Rama Himalayan University (SRHU)/Study Site


.....
Dr. Mukesh Bijalwan
Registrar
Swami Rama Himalayan University
Swami Ram Nagar,
Jolly Grant, Dehradun
Uttarakhand 248016



Witness: Prateek Dhyani (Attorney)

Signature of the KV Clinical Research Pvt Ltd/KVCR:


.....
Dr. Kirti Kumar Patel
Founder & Chief Operating Officer,
KV Clinical Research Pvt Ltd,
Office No. 616, Sixth Floor
Golden Trade Center, New Rajendra Nagar
Raipur – 492001, Chhattisgarh, India



Witness: Manisha Aggarwal



ATTESTED
(RAJENDER SINGH NEGI)
Advocate & NOTARY
Chamber No. 92, 1st Floor
Opposite Bar Office
Colliery Road, Dehradun (Uttarakhand)



Government of India
Form GST REG-06
[See Rule 10(1)]

Registration Certificate

Registration Number : 22AAICK3564G1ZN

1.	Legal Name	K V CLINICAL RESEARCH PRIVATE LIMITED			
2.	Trade Name, if any	K V CLINICAL RESEARCH PRIVATE LIMITED			
3.	Constitution of Business	Private Limited Company			
4.	Address of Principal Place of Business	SIXTH FLOOR, 617, GOLDEN TRADE CENTER, NEW RAJENDRA NAGAR, RAIPUR, Raipur, Chhattisgarh, 492001			
5.	Date of Liability				
6.	Period of Validity	From	27/10/2020	To	Not Applicable
7.	Type of Registration	Regular			
8.	Particulars of Approving Authority	Centre			
Signature					
Name		AJAY KUMAR ARYA			
Designation		Superintendent			
Jurisdictional Office		Raipur - 7			
9. Date of issue of Certificate		27/10/2020			
Note: The registration certificate is required to be prominently displayed at all places of business in the State.					

This is a system generated digitally signed Registration Certificate issued based on the approval of application granted on 27/10/2020 by the jurisdictional authority.





GSTIN	22AAICK3564G1ZN
Legal Name	K V CLINICAL RESEARCH PRIVATE LIMITED
Trade Name, if any	K V CLINICAL RESEARCH PRIVATE LIMITED

Details of Additional Places of Business

Total Number of Additional Places of Business in the State 0





GSTIN	22AAICK3564G1ZN
Legal Name	K V CLINICAL RESEARCH PRIVATE LIMITED
Trade Name, if any	K V CLINICAL RESEARCH PRIVATE LIMITED

Details of Managing / Whole-time Directors and Key Managerial Persons

1		Name	KIRTI KUMAR PATEL
		Designation/Status	director
		Resident of State	Chhattisgarh
2		Name	VIKAS RAMAN CHANDRAKAR
		Designation/Status	DIRECTOR
		Resident of State	Gujarat






आयकर विभाग
INCOME TAX DEPARTMENT



भारत सरकार
GOVT. OF INDIA

ई-स्थायी लेखा संख्या कार्ड
e - Permanent Account Number (e-PAN) Card
AAICK3564G

नाम / Name

K V CLINICAL RESEARCH PRIVATE LIMITED

निगमन/गठन की तारीख

Date of Incorporation / Formation

08/10/2020



Signature Not
Verified

Digitally signed by Income Tax
PAN Services Unit, NSDL
eGovernance
Date: 2020.10.08 05:52:11
GMT+05:30
Reason: NSDL ePAN Sign
Location: Mumbai

- ✓ Permanent Account Number (PAN) facilitate Income Tax Department linking of various documents, including payment of taxes, assessment, tax demand tax arrears, matching of information and easy maintenance & retrieval of electronic information etc. relating to a taxpayer. स्थायी लेखा संख्या (पैन) एक करदाता से संबंधित विभिन्न दस्तावेजों को जोड़ने में आयकर विभाग को सहायक होता है, जिसमें करों के भुगतान, आकलन, कर मांग, टैक्स बकाया, सूचना के मिलान और इलेक्ट्रॉनिक जानकारी का आसान रखरखाव व बहाली आदि भी शामिल है।
- ✓ Quoting of PAN is now mandatory for several transactions specified under Income Tax Act, 1961 (Refer Rule 114B of Income Tax Rules, 1962) आयकर अधिनियम, 1961 के तहत निर्दिष्ट कई लेनदेन के लिए स्थायी लेखा संख्या (पैन) का उल्लेख अब अनिवार्य है (आयकर नियम, 1962 के नियम 114B, का संदर्भ लें)
- ✓ Possessing or using more than one PAN is against the law & may attract penalty of upto Rs. 10,000. एक से अधिक स्थायी लेखा संख्या (पैन) का रखना या उपयोग करना, कानून के विरुद्ध है और इसके लिए 10,000 रुपये तक का दंड लगाया जा सकता है।
- ✓ The PAN Card enclosed contains Enhanced QR Code which is readable by a specific Android Mobile App. Keyword to search this specific Mobile App on Google Play Store is "Enhanced QR Code Reader for PAN Card". संलग्न पैन कार्ड में एनहांस क्यूआर कोड शामिल है जो एक विशिष्ट एंड्रॉइड मोबाइल ऐप द्वारा पठनीय है। Google Play Store पर इस विशिष्ट मोबाइल ऐप को खोजने के लिए कीवर्ड "Enhanced QR Code Reader for PAN Card" है।

Cut

आयकर विभाग INCOME TAX DEPARTMENT स्थायी लेखा संख्या कार्ड Permanent Account Number Card AAICK3564G नाम / Name K V CLINICAL RESEARCH PRIVATE LIMITED निगमन/गठन की तारीख Date of Incorporation/Formation 08/10/2020	भारत सरकार GOVT. OF INDIA इस कार्ड के खोने/पाने पर कृपया सूचित करें/नोट करें: आयकर पैन सेवा इकाई, एन एस डी यू 5 वीं मंजिल, मंत्री स्टर्लिंग, प्लॉट नं. 341, सर्वे नं. 997/8, मॉडल कॉलोनी, दीप बंगला चौक के पास, पुणे - 411 016. If this card is lost / someone's lost card is found, please inform / return to : Income Tax PAN Services Unit, NSDL 5th Floor, Mantri Sterling, Plot No. 341, Survey No. 997/8, Model Colony, Near Deep Bungalow Chowk, Pune - 411 016. Tel: 91-20-2721 8080, Fax: 91-20-2721 8081 e-mail: tininfo@nsdl.co.in
--	---

Electronically issued and Digitally signed ePAN is a valid mode of issue of Permanent Account Number (PAN) post amendments in clause (c) in the Explanation occurring after sub-section (8) of Section 139A of Income Tax Act, 1961 and sub-rule (6) of Rule 114 of the Income Tax Rules, 1962. For more details, click [here](#)

[Handwritten Signature]





GOVERNMENT OF INDIA
MINISTRY OF CORPORATE AFFAIRS

Central Registration Centre

Certificate of Incorporation

[Pursuant to sub-section (2) of section 7 and sub-section (1) of section 8 of the Companies Act, 2013 (18 of 2013) and rule 18 of the Companies (Incorporation) Rules, 2014]

I hereby certify that K V CLINICAL RESEARCH PRIVATE LIMITED is incorporated on this Eighth day of October Two thousand twenty under the Companies Act, 2013 (18 of 2013) and that the company is limited by shares.

The Corporate Identity Number of the company is U73200CT2020PTC010704.

The Permanent Account Number (PAN) of the company is AAICK3564G *

The Tax Deduction and Collection Account Number (TAN) of the company is JBPK03524D *

Given under my hand at Manesar this Eighth day of October Two thousand twenty .

DS MINISTRY OF
CORPORATE AFFAIRS 6

Digital Signature Certificate
Mr. ARVIND KUMAR BUNKAR
Deputy Registrar Of Companies
For and on behalf of the Jurisdictional Registrar of Companies
Registrar of Companies
Central Registration Centre

Disclaimer: This certificate only evidences incorporation of the company on the basis of documents and declarations of the applicant(s). This certificate is neither a license nor permission to conduct business or solicit deposits or funds from public. Permission of sector regulator is necessary wherever required. Registration status and other details of the company can be verified on www.mca.gov.in

Mailing Address as per record available in Registrar of Companies office:

K V CLINICAL RESEARCH PRIVATE LIMITED
C/O NAVKAR ASSOCIATES RAJENDRA NAGAR, NEAR BSNL
EXECUTIVE OFFICE, RAIPUR, Raipur, Chattisgarh, India, 492001

* as issued by the Income Tax Department

ATTESTED
(RAJENDER SINGH NEGI)
Advocate & NOTARY
Chamber No. 92, 1st floor
Opposite Bar Office
Central Registration Centre
Raipur, Chattisgarh





C L A S S I C

HDFC BANK LTD. SHOP NO 3.4, LALGANGA BUSINESS PARK
PACHPEDI NAKA, RAIPUR, RAIPUR-492001, CHHATTISGARH
RTGS / NEFT IFSC : HDFC0001280

D	D	M	M	Y	Y	Y	Y		
Valid for 3 months only									

Pay

Or Bearer

Rupees रुपये

या धारक को

अदा करें

₹

A/c. No.
खता क्र.

50200053851767

Brn: 1280 Pdt: 1313
ASCENT CA

For K V CLINICAL RESEARCH PRIVATE LIMITED

Payable at par through clearing/transfer at all branches of HDFC BANK LTD

Authorised Signatories

Please sign above / कृपया यहाँ हस्ताक्षर करें

⑈000126⑈ 492240004⑈ 018724⑈ 29

[Handwritten signature]

